To target the vessels that persisted after SHP099 treatment, we sought to inhibit Ang2/TIE2‐induced tumor angiogenesis that is mediated by the PI3K/AKT pathway (Augustin et al,2009; Saharinen et al,2017). Here, AKT1 is linked to neoplasm.